昊海生科(688366.SH):子公司角膜塑形用硬性透氣接觸鏡產品獲得醫療器械註冊批准
格隆匯12月27日丨昊海生科(688366.SH)公佈,公司控股子公司深圳市新產業眼科新技術有限公司(“深圳新產業”)於近日收到國家藥品監督管理局頒發的關於角膜塑形用硬性透氣接觸鏡產品(“OK鏡”)的《中華人民共和國醫療器械註冊證》。
適用範圍:該產品適用於滿足説明書要求,並且近視度數在-1.00D~-4.00D之內(包含-1.00D和-4.00D),散光度數不超過1.50D的配戴者近視的暫時矯正。
該產品是利用公司自主研發的光學設計系統,基於公司控股子公司Contamac Holdings Limited的高透氧材料研製的新型角膜塑形用硬性透氣接觸鏡產品。
公司已於2021年通過收購上海亨泰視覺科技有限公司、廈門南鵬光學有限公司,獲得了“myOK邁兒康”以及“亨泰Hiline”兩款OK鏡產品在中國大陸地區的獨家代理經銷權。該產品的獲批,豐富了公司OK鏡產品的產品系列,擴充了公司在近視防控及管理領域的佈局,不斷滿足患者及多元化的市場需求,進一步增強公司產品的綜合競爭力和市場拓展能力,對公司經營發展具有積極作用。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.